AADI BIOSCIENCE, INC.
AADI US00032Q1040
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 53% | -49% | -84% | 54% | 4% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Ball Bryan O |
2.35 USD |
2,147 Sold |
5,045 USD |
01/03/2025 | 03/03/2025 |
| Giacobello Scott M. CFO |
2.35 USD |
2,806 Sold |
6,594 USD |
01/03/2025 | 03/03/2025 |
| Lennon David James CEO |
2.35 USD |
5,690 Sold |
13,372 USD |
01/03/2025 | 03/03/2025 |
| Lennon David James CEO |
1.94 USD |
9,689 Sold |
18,797 USD |
02/10/2024 | 03/10/2024 |
| Desai Neil CB |
1.71 USD |
40,000 Sold |
68,316 USD |
03/09/2024 | 03/09/2024 |
| Desai Neil CB |
1.34 USD |
5,652 Sold |
7,595 USD |
01/08/2024 | 05/08/2024 |
| Desai Neil CB |
1.41 USD |
18,933 Sold |
26,705 USD |
01/08/2024 | 02/08/2024 |
| Desai Neil CB |
1.50 USD |
15,415 Sold |
23,055 USD |
01/08/2024 | 01/08/2024 |
| Desai Neil CB |
1.34 USD |
8,652 Sold |
11,612 USD |
01/07/2024 | 02/07/2024 |
| Desai Neil CB |
1.45 USD |
31,348 Sold |
45,605 USD |
01/07/2024 | 01/07/2024 |